

BIOGRAPHICAL SKETCH			
NAME Jacobo E. Mintzer, M.D.		POSITION TITLE Staff Physician, Ralph H. Johnson VA Medical Center Professor, Dept. of Neurosciences & Psychiatry Director, Division of Translational Research, Neurosciences Department	
eRA COMMONS USER NAME mintzerj			
EDUCATION/TRAINING			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Latin American Rabbinical Seminary, Buenos Aires, Argentina	BA	1972-78	Jewish Cultural & Rabbinical Studies
Buenos Aires University, Buenos Aires, Argentina	MD	1972-78	
Hadassah-Hebrew University, Jerusalem, Israel	Internship	1979-80	
Hadassah-Hebrew University, Jerusalem, Israel	Residency	1980-85	Psychiatry
University of California, Los Angeles, CA	Fellowship	1985-87	Geriatric Psychiatry

A. Previous Employment and Experience

1987 - 1991	Assistant Professor, Psychiatry, University of Miami Medical School, Miami, FL
1988 - 1991	Director, Psychiatric Module, Geriatric Educational Center, Univ. Miami Medical School, Miami, FL
1988 - 1991	Director, Geriatric Psychiatry Fellowship Program, University of Miami Medical School, Mt. Sinai Hospital, and Miami Memory Disorders Clinic, Miami, FL
1989 - 1991	Co-Director, Caritas Nursing Home Project, Miami, FL
1991 - 1996	Associate Professor, Psychiatry, Medical University of South Carolina (MUSC), Charleston, SC
1991 - 2006	Director, Geriatric Psychiatry Fellowship Program, MUSC, Charleston, SC
1991 - 2006	Director, Geriatric Psychiatry Program, MUSC, Charleston, SC
1992 - 1996	Floor Coordinator, Institute of Psychiatry, MUSC, Charleston, SC
1997 - 1998	Associate Professor, Neurology, MUSC, Charleston, SC
1997 –	Co-Director, Alzheimer's Research and Clinical Programs, MUSC, Charleston, SC
1998 - 2004	Professor, Psychiatry and Neurology, MUSC, Charleston, SC
2000	Health Care Research Investigator, Center for Health Care Research, MUSC, Charleston, SC
2001 - 2002	Scholar, Geriatric Psychiatry, Health Science Foundation & AstraZeneca, MUSC, Charleston, SC
2001 –	Staff Physician, Ralph H. Johnson VA Medical Center, Charleston, S.C.
2000 - 2002	Faculty Advisory Committee, Psychiatry, MUSC, Charleston, SC
2002 - 2004	Associate Director, Neuroscience Institute for Alzheimer's Research, MUSC, Charleston, SC
2004 –	Professor, Neurology, Physiology & Neurosciences, MUSC, Charleston, SC
2003 - 2006	Chief, Division of Geriatric Psychiatry, Department of Psychiatry, MUSC, Charleston, SC
2003 - 2004	Professor, Physiology and Neurosciences, MUSC, Charleston, SC
2006 –	Primary appointment: Department of Neurosciences, Medical University of South Carolina Secondary appointment Department of Psychiatry
2006 –	Director, Division of Translational Research, Neurosciences, MUSC, Charleston, SC

Awards and Honors

1992 - 98	Reviewer, National Institute on Aging, Ad Hoc Programs
1992 -	Member, South Carolina Commission on Aging. Alzheimer's Advisory Committee
1993 -	Founding Member, Low Country Chapter, Alzheimer's Association
1995 -	Member, Governor's Advisory Council to the Alzheimer's Disease and Related Disorders Resource Coordination Center
1996 - 07	Best Doctors in America
1997 - 99	Member, Clinical Centers and Special Projects Review Committee of the National Institute of Mental Health (NIMH) Initial Review Group

- 1999 - Member, International Psychogeriatric Association, Committee on Behavioral and Psychiatric Symptoms of Dementia
- 2000 - 01 Senior Scientific Advisor, National Institute of Mental Health
- 2001 - 02 Treasurer Elect, American Association of Geriatric Psychiatry
- 2001 - 03 Chair, Scientific Committee for the 2003 Meeting of International Psychogeriatric Association
- 2002 - 03 Treasurer, American Association of Geriatric Psychiatry
- 2003 - 07 International Psychogeriatric Association (IPA) Board of Directors
- 2004 Distinguished Fellow; American Psychiatric Association
- 2005 - 07 Treasurer Elect, International Psychogeriatric Association (IPA)
- 2007 - 09 Treasurer, International Psychogeriatric Association (IPA)
- 2009 - International Psychogeriatric Association (IPA) President-Elect

B. Selected Publications (out of 160; presented in chronological order)

Book Chapter

Mintzer J, Hendrie H, Faison W: Minority and Sociocultural Issues. Chapter 51.6 d (p. 3813-3822). Kaplan & Sadock's Comprehensive Textbook of Psychiatry. Eighth Edition – Volume 2. Lippincott Williams & Wilkins, New York. (2005)

Articles

1. Rubey R, **Mintzer J**. Behavioral and Psychologic Symptoms of Dementia: How Does This Conceptualization Help Us? *Current Psychosis & Therapeutics Reports* 2005, 3:32-37.
2. Faison W, **Mintzer J**. The growing, ethnically diverse aging population. Is our field advancing with it? *Am J Geriatr Psychiatry* 13:7, July 2005; pages 541-544.
3. Tariot P, Raman R, Jakimovich L, Schneider L, Porsteinsson A, Thomas R, **Mintzer J**, et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial. *Am J Geriatr Psychiatry* 2005: Nov. 13:11; 942-949.
4. Reynolds J, **Mintzer J**. Alzheimer Disease Update. New Targets, New Options. *Drug Benefit Trends*. 2005;17(2): 83-88, 91-95.
5. **Mintzer J**, Greenspan A, Caers I, Hove I, Kushner S, Weiner M, Gharabawi G, Schneider L. Risperidone in the treatment of psychosis of Alzheimer's Disease: results from a prospective clinical trial. *Am J Geriatric Psychiatry*, 2006 March; 14(3): 280-291.
6. Tariot P, Schneider L, Katz A, **Mintzer J**, Street J, Copenhaver M, Williams-Hughes C. Quetiapine treatment of psychosis associated with dementia: a Double-Blind, randomized, Placebo-Controlled clinical trial. *Am J Geriatric Psychiatry* 2006 Sep; 14(9):767-776. Epub 2006 Aug 11.
7. **Mintzer, J**. Introduction: the clinical impact of agitation in various psychiatric disorders: management consensus and controversies. *J Clin Psychiatry*. 2006; 56 Suppl 10:3-5.
8. Martin BK, Frangakis, CE, Rosenberg, PB, **Mintzer, J**, Katz, IR, et al. Design of Depression in Alzheimer's Disease Study-2. *Am J Geriatr Psychiatry*. 2006 Nov; 14(11):920-30.
9. **Mintzer J**. The Diagnosis and Treatment of Dementias and Alzheimer's Disease in Five European Countries: An Analytical Report. *IPA Bulletin*, January 2007. 8-10.
10. Zhong KX, Tariot PN, **Mintzer J**, Minkwitz MC, Devine NA. Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. *Curr Alzheimer Res*. 2007 Feb;4(1):81-93.
11. Wagner MT, Wymer JH, Carozzi NE, Bachman D, Walker A, **Mintzer J**; Alzheimer Study Group. Preliminary examination of progression of Alzheimer's disease in a rural Southern African American cohort. *Arch Clin Neuropsychol*. 2007 Mar;22(3):405-14. Epub 2007 Feb.12
12. Faison WE, Schultz SK, Aerssens J, Alvidrez J, Anand R, Farrer LA, Jarvik L, Manly J, McRae T, Murphy GM, Olin JT, Regier D, Sano M, **Mintzer JE**. Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future. *Int Psychogeriatr*. 2007 Jun;19(3):539-58. Epub 2007 Apr 23.
13. Katz I, de Deyn P, **Mintzer J**, Greenspan A, Zhu Y, Brodaty H: The efficacy and safety of Risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. *Int J Geriatr Psychiatry*. 2007 May;22(5):475-84.
14. Broadway J, **Mintzer J**. The many faces of psychosis in the elderly. *Current Opinion in Psychiatry*. 2007 Nov; 20(6):551-8.
15. **Mintzer JE**, Tune LE, Breder CD, Swanink R, Marcus RN, McQuade RD, Forbes A. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized,

double-blind, placebo-controlled assessment of three fixed doses. *Am J Geriatr Psychiatry*. 2007 November; 15(11):918-31.

16. Porsteinsson AP, Grossberg GT, **Mintzer J**, Olin JT; Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. *Curr Alzheimer Res*. 2008 Feb; 5(1):83-9.
17. Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Mayorga AJ, Wang D, Brashear HR, Nye JS, GAL-INT-11/18 Study Group.* Safety and efficacy of galantamine in subjects with mild cognitive impairment. *Neurology*. 2008 May 27; 70(22):2024-35. Epub 2008 Mar 5.
* Dr. **Mintzer** was apart of the GAL-INT-11/18 Study Group.
18. Kirbach S, Simpson K, Nietert PJ, **Mintzer J**. A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease. *Clin Drug Investig*. 2008; 28(5):291-303.
19. Salloway S, **Mintzer J**, Weiner MF, Cummings JL. Disease-modifying therapies in Alzheimer's disease. *Alzheimers Dement*. 2008 Mar; 4(2):65-79. Epub 2008 Feb 20.
20. McNeal KM, Meyer RP, Lukacs K, Senseney A, **Mintzer J**. Using risperidone for Alzheimer's dementia-associated psychosis. *Expert Opin Pharmacother*. 2008 Oct; 9(14):2537-43.
21. Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ, Alzheimer Disease Cooperative Study.* High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. *JAMA*. 2008 Oct 15; 300(15): 1774-83.
* Dr. **Mintzer** was apart of the Alzheimer Disease Cooperative Study.
22. Laditka JN, Laditka SB, Cornman CB, Porter CN, Davis DR, **Mintzer J**. Notably higher rates of vascular risk factors and dementia among African Americans in South Carolina: opportunities for public health intervention. *J SC Med Assoc*. 2008 Oct; 104(7):219-22.

C. Research Support

ONGOING

- | | | |
|--|-----------------|---|
| 5 T32 AG21794-04
NIH/NIA
Institute for Research Minority Training on Mental Health and Aging
The aim of IRMMA is to recruit, Train, and retain promising minority individuals from post-doctoral programs in research areas that relate to mental health and aging.
Role: Director | Mintzer (PI) | 09/01/2002-10/31/2008 (No-Cost Extension) |
| 1 U01 MH066176-02
NIH/NIMH
Depression in Alzheimer's Disease Study – 2 (DIADS-2)
This is a 12-week placebo-controlled clinical trial assessing the efficacy and safety of Sertraline for DSM-IV major depression in Alzheimer's disease. | Mintzer (PI) | 04/01/2003-02/28/2009 (No-Cost Extension) |
| 1 R01 AG021488-01
NIH/NIA
Antipsychotic Discontinuation in Alzheimer's Disease
The primary aim of this project is to evaluate the ideal time of treatment with atypical antipsychotics in demented, agitated patients. | Mintzer (Co-PI) | 09/30/2003-08/31/2009 |
| ADCS-022 VN
Alzheimer's Disease Cooperative Study
A Randomized, Double-Blind, Placebo-Controlled Trial of Valproate to Attenuate the Progression of Alzheimer's Disease.
The goal of this trail is to determine whether chronic Valproate therapy delays the emergence of agitation and/or psychosis in outpatients with probable Alzheimer's disease (AD) who have not experienced agitation and psychosis in their illness. | Mintzer (PI) | 07/01/2003-06/30/2010 |
| ADCS-027-DHA | Mintzer (PI) | 01/01/2007– 06/30/2010 |
-

Alzheimer's Disease Cooperative Study

Trial of the effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease

The primary objective of the study is to determine if chronic use of Docosahexaenoic Acid (DHA) changes the progression of Alzheimer's disease

ADCS-RI-B0341002

Mintzer (PI)

03/03/2008 – 06/30/2010

Alzheimer's Disease Cooperative Study

Pfizer, Inc.

A Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study Evaluating the Efficacy and Safety of Eighteen Months of Treatment with PF-04494700 (TTP488) in Participants with Mild to Moderate Alzheimer's Disease

The primary objective of the study is to determine if chronic use of PF-04494700 changes the progression of Alzheimer's disease.

ELN 115727-301/302

Mintzer (PI)

01/16/2008 – 01/31/2011

Elan Pharmaceuticals

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (AAB-002, ELN115727) in Patients with Mild to Moderate Alzheimer's Disease who are Apolipoprotein E4 Non-Carriers

The primary objective of the study is to evaluate the safety and efficacy of Bapineuzumab to slow the progression of Alzheimer's Disease.

H6L-MC-LFAN

Mintzer (PI)

08/01/2008 – 07/31/2010

Lilly Research Laboratories/Eli Lilly and Company

Effect of Gamma Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo

The primary objective of the study is to evaluate the effect of gamma secretase inhibition on the progression of Alzheimer's Disease.

PENDING

1R01AG031348-01

Mintzer (PI)

09/15/2008 – 06/30/2013

NIH/NIA Citalopram Treatment for Agitation in Alzheimer's Dementia (CITAD)

The goal of this study is to explore the safety and efficacy of Citalopram in treating agitation in Alzheimer's Disease

ADCS-IGIV

Mintzer (PI)

10/29/2008 – 10/28/2011

Alzheimer's Disease Cooperative Study

Baxter Healthcare

A Randomized, Double-Blind, Placebo-Controlled, Two Dose Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease

The primary objective of the study is to determine the safety and effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the treatment of mild to moderate Alzheimer's disease

ABE4427g

Mintzer (PI)

TBD

Genetech, Inc.

A Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous MABT5102A Administered in a Single-Dose, Dose-Escalation Stage followed by a Multidose, Parallel-Treatment Stage in Patients with Mild to Moderate Alzheimer's Disease

The primary objective of the study is to determine the safety and efficacy of intravenous MABT5102A.
